Skip to main content
Gland Pharma Limited logo

Gland Pharma Limited — Investor Relations & Filings

Ticker · GLAND ISIN · INE068V01023 LEI · 335800JJVDY5R6KF5K34 BSE.NS Manufacturing
Open in API
Filings indexed 680 across all filing types
Latest filing 2022-07-28 Regulatory Filings
Country IN India
Listing BSE.NS GLAND

About Gland Pharma Limited

https://glandpharma.com

Gland Pharma Limited is a specialized Contract Development and Manufacturing Organization (CDMO) focused on injectable formulations. The company operates primarily through a business-to-business (B2B) model, providing development and manufacturing services for a diverse range of sterile injectables. Its portfolio encompasses complex generics across various therapeutic areas, including oncology, ophthalmology, anti-infectives, and orthopedics. Gland Pharma maintains a vertically integrated supply chain, ensuring control over critical raw materials and active pharmaceutical ingredients. The company serves a global market, with a significant presence in regulated regions such as the United States, Europe, Canada, and Australia. Its manufacturing facilities adhere to international quality standards and hold approvals from major regulatory bodies. Key strengths include expertise in niche segments like heparin and enoxaparin, alongside a robust pipeline of complex delivery systems.

Recent filings

Filing Released Lang Actions
Schedule of Analysts/Institutional Investor Meet/Con. Call
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges notifying them of the schedule of upcoming analyst and institutional investor meetings. It references Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, which governs disclosure of material events. The content is purely an announcement of scheduled meetings with investors and analysts, without any financial data, report, or detailed presentation. The document length is short (1723 characters), and it does not contain financial statements or detailed analysis. Therefore, it is not an investor presentation (IP) or earnings release (ER), but rather a regulatory announcement about investor meetings. This fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-07-28 English
Transcript of Analysts/Institutional Investor Meet/Con. Call
Call Transcript Classification · 100% confidence The document is a detailed transcript of an earnings conference call for the first quarter of fiscal year 2023 (Q1 FY'23) for Gland Pharma Limited. It includes management's opening remarks, financial performance overview, discussion of business highlights, and a Q&A session with analysts. The text explicitly mentions it is an "Earnings call Transcript" and contains detailed financial data such as revenue, profit, margins, R&D expenses, cash flow, and CAPEX. The presence of a full transcript of the call, including management commentary and Q&A, clearly identifies this as a Call Transcript (CT).
2022-07-27 English
Schedule of Analysts/Institutional Investor Meet/Con. Call
Investor Presentation Classification · 80% confidence The document is a letter addressed to stock exchanges notifying them of the schedule of upcoming analyst and institutional investor meetings. It references regulatory compliance (SEBI Listing Obligations) and provides dates and types of meetings. The content is an announcement about meetings rather than a report or transcript of the meetings themselves. It does not contain financial data, earnings, or detailed presentations. Therefore, it fits the category of Investor Presentation announcements or related updates. However, since it is only a schedule notification and not the presentation itself, the best fitting category is Investor Presentation (IP), which includes detailed presentations for investors focusing on financials, strategy, and market position, or announcements related to such meetings. Given the limited content, the confidence is moderate to high.
2022-07-27 English
Schedule of Analysts/Institutional Investor Meet/Con. Call
Investor Presentation Classification · 85% confidence The document is a letter addressed to stock exchanges notifying them of the schedule of analyst and institutional investor meetings. It references compliance with SEBI regulations and provides dates and types of meetings (virtual calls and in-person meetings). There is no financial data, report content, or detailed presentation included. The document is an announcement of upcoming investor meetings rather than the meetings' transcripts or presentations themselves. Therefore, it fits best under the category of Investor Presentation (IP) as it relates to investor communications and meetings, even though it is a schedule notice rather than the presentation itself. Given the short length and nature, it is not a full report or transcript but an update related to investor relations.
2022-07-25 English
Newspaper Advertisements
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges regarding the publication of a newspaper advertisement for the company's unaudited financial results for Q1FY2023. It references Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) and mentions that the advertisement was published in newspapers. The document itself is short (1260 characters) and does not contain actual financial statements or detailed financial analysis, but rather serves as a notification or announcement of the publication of financial results. According to the 'MENU VS MEAL' rule, such a document is an announcement about a report or results being published, not the report itself. Therefore, it should be classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-07-21 English
Recording of Analysts/Institutional Investor Meet/Con. Call
Regulatory Filings Classification · 95% confidence The document is a short letter addressed to stock exchanges, notifying them about the earnings call recording for the quarter ended June 30, 2022. It mentions the date of the call and provides a weblink to the audio recording. There is no detailed financial data or transcript included, only an announcement that the recording is available on the company's website. The document length is only 1162 characters, which is very short and consistent with an announcement rather than a full report or transcript. According to the rules, such a notification about the availability of an earnings call recording is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement and does not contain the full transcript or financial results itself.
2022-07-20 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.